Drug intelligence / Profile preview

G4M-005

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

G4M-005 is a polyherbal formulation studied for its potential therapeutic effects against viral infections, specifically chikungunya virus (CHIKV) infection. It is based on traditional Indian herbal medicine, including Withania somnifera (Ashwagandha). The formulation has been evaluated in vivo in animal models for its ability to alleviate arthralgia and reduce viral load following CHIKV infection. The mechanism of action likely involves immunomodulatory and anti-inflammatory effects typical of Withania somnifera-based formulations, though precise molecular targets are not fully characterized.

Beyond the preview

Go deeper on G4M-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G4M-005.

Explore the full profile